Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

This will be a double-blind comparative study, performed in pediatric subjects (Age 6-11) traveling to developing regions with a known high incidence of traveler's diarrhea. The subjects will be suffering from acute diarrhea for at least 12 hours, without symptoms of systemic infection.

开始日期2024-06-01

申办/合作机构

RedHill Biopharma Ltd.

NCT04027894 / Not yet recruiting临床2期

Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years

This will be a double blind comparative study, performed in pediatric subjects (Age 12-17) traveling to developing regions with a known high incidence of traveler's diarrhea. The subjects will be suffering from acute diarrhea for at least 12 hours, without symptoms of systemic infection.

开始日期2024-01-01

申办/合作机构

RedHill Biopharma Ltd.

NCT04082780 / Completed临床2期

A Double-Blind Randomized Placebo-Controlled Trial of Rifamycin SV MXX in Minimal Hepatic Encephalopathy (RIVET Trial)

This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.

开始日期2019-09-01

申办/合作机构

Hunter Holmes McGuire VA Medical Center

100 项与利福霉素钠相关的临床结果

登录后查看更多信息

100 项与利福霉素钠相关的转化医学

登录后查看更多信息

100 项与利福霉素钠相关的专利（医药）

登录后查看更多信息

1,953

项与利福霉素钠相关的文献（医药）

2024-01-15·ChemMedChem

Discovery of (2‐(4‐Substituted phenyl)quinolin‐4‐yl)(4‐isopropylpiperazin‐1‐yl)methanone Derivatives as Potent Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Article

作者: Xu, Guangzhao ; Li, Honggang ; Wang, Xue ; Zhu, Dongqi ; Zhang, Lei ; Zhang, Lihui ; Wang, Xiaojing

Abstract:

Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an increasingly important role in the treatment of hyperlipidemia. In pursuit of potent small molecules that block the PCSK9/low‐density lipoprotein receptor (LDLR) protein−protein interaction (PPI), a series of 2‐phenylquinoline‐4‐carboxylic acid derivatives were designed and synthesized based on previously derived molecules. In the in vitro PPI inhibition test, compounds M1, M12, M14, M18 and M27 exhibited potent activities with IC50 values of 6.25 μM, 0.91 μM, 2.81 μM, 4.26 μM and 0.76 μM, respectively, compared with SBC‐115337 (IC50 value of 9.24 μM). Molecular docking and molecular dynamics simulations revealed the importance of hydrophobic interactions in the binding of inhibitors to the PPI interface of PCSK9. In LDLR expression and LDL uptake assays, the tested compounds M1, M12 and M14 were found to restore LDLR expression levels and to increase the extracellular LDL uptake capacity of HepG2 cells in the presence of exogenous PCSK9. Collectively, novel small‐molecule PCSK9/LDLR PPI inhibitors (especially M12) with in vitro lipid lowering ability, were discovered as lead compounds for further development of hypolipidemic drugs.

2024-01-11·Microbiology spectrum

Genome-wide screen reveals cellular functions that counteract rifampicin lethality in Escherichia coli

Article

作者: Shi, Xiao-Jie ; Fu, Han ; Zhao, Guo-Ping ; Lyu, Liang-Dong ; Wang, Yu

ABSTRACT:

The antibacterial activity of rifamycins specifically relies on the inhibition of transcription by directly binding to the β-subunit of bacterial DNA-dependent RNA polymerase (RNAP). However, its killing efficacy is substantially diminished in most gram-negative bacteria. To systematically reveal the cellular functions that counteract rifamycin-mediated killing in the gram-negative model organism Escherichia coli , we performed a genome-wide Tn5 transposon-mediated screen to identify mutants with altered susceptibility to rifampicin. Combined with targeted gene knockouts, our results showed that the β-barrel assembly machinery plays a crucial role in restricting rifampicin from entering the cell, whereas mutants deficient in other cellular permeability barriers, such as lipopolysaccharide and enterobacterial common antigen, had no such effect. At bactericidal concentrations, the killing efficacy of rifampicin was strongly influenced by cellular functions, including iron acquisition, DNA repair, aerobic respiration, and carbon metabolism. Although iron acquisition de facto has a strong impact or dependence on cellular redox, our results suggest that their effects on rifampicin efficacy do not rely on hydroxyl radical formation. We provide evidence that maintenance of DNA replication and transcription-coupled nucleotide excision repair protects E. coli cells against rifampicin killing. Moreover, our results showed that sustained aerobic respiration and carbon catabolism diminish rifampicin’s killing efficacy, and this effect relies on the inhibition of transcription but not on translation. These findings suggest that the killing efficacy of rifamycins is largely determined by cellular responses upon the inhibition of RNAP and may expand our knowledge of the action mechanisms of rifamycins.

IMPORTANCE:

Rifamycins are a group of antibiotics with a wide antibacterial spectrum. Although the binding target of rifamycin has been well characterized, the mechanisms underlying the discrepant killing efficacy between gram-negative and gram-positive bacteria remain poorly understood. Using a high-throughput screen combined with targeted gene knockouts in the gram-negative model organism Escherichia coli , we established that rifampicin efficacy is strongly dependent on several cellular pathways, including iron acquisition, DNA repair, aerobic respiration, and carbon metabolism. In addition, we provide evidence that these pathways modulate rifampicin efficacy in a manner distinct from redox-related killing. Our findings provide insights into the mechanism of rifamycin efficacy and may aid in the development of new antimicrobial adjuvants.

2024-01-01·Archives of toxicology

Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site

Article

作者: Theile, Dirk ; Weiss, Johanna ; Pávek, Petr ; Phondeth, Lottida ; Nilles, Julie ; Kamaraj, Rajamanikkam ; Haefeli, Walter E

Abstract:

Physiology-based pharmacokinetic modeling suggests that rifabutin can out-balance P-glycoprotein (P-gp) induction by concurrent P-gp inhibition. However, clinical or experimental evidence for this Janus-faced rifabutin effect is missing. Consequently, LS180 cells were exposed to a moderately (2 µM) and strongly (10 µM) P-gp-inducing concentration of rifampicin or rifabutin for 6 days. Cellular accumulation of the fluorescent P-gp substrate rhodamine 123 was evaluated using flow cytometry, either without (induction only) or with adding rifamycin drug to the cells during the rhodamine 123 efflux phase (induction + potential inhibition). Rhodamine 123 accumulation was decreased similarly by both drugs after 6-day exposure (2 µM: 55% residual fluorescence compared to non-induced cells, P < 0.01; 10 µM: 30% residual fluorescence compared to non-induced cells, P < 0.001), indicating P-gp induction. Rhodamine 123 influx transporters mRNA expressions were not affected, excluding off-target effects. Acute re-exposure to rifabutin, however, considerably re-increased rhodamine 123 accumulation (2 µM induction: re-increase by 55%, P < 0.01; 10 µM induction: 49% re-increase, P < 0.001), suggesting P-gp inhibition. In contrast, rifampicin only had weak effects (2 µM induction: no re-increase; 10 µM induction: 16% re-increase; P < 0.05). Molecular docking analysis eventually revealed that rifabutin has a higher binding affinity to the inhibitor binding site of P-gp than rifampicin (ΔG (kcal/mol) = −11.5 vs −5.3). Together, this study demonstrates that rifabutin can at least partly mask P-gp induction by P-gp inhibition, mediated by high affinity binding to the inhibitory site of P-gp.

项与利福霉素钠相关的新闻（医药）

2024-06-03

·PRNewswire

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

New Chinese patent notice of allowance issued covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response [1]. Provides protection for opaganib's potential use in combination with a range of approved and in-development (ICIs) across a growing range of indications [2] through 2040 ICIs have become a cornerstone in cancer treatment, having been hailed as a major breakthrough by oncologists, with the global ICI market expected to exceed $100 billion by 2028, including Merck's Keytruda (pembrolizumab) and BMS' Yervoy (ipilimumab) [3] Opaganib, a host-directed and potentially broad acting twice-daily oral, small molecule with a demonstrated safety & efficacy profile, is in development for multiple oncology, viral and inflammatory indications, including COVID-19, Ebola, acute respiratory distress syndrome (ARDS) and two U.S. government-sponsored countermeasures programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure TEL-AVIV, Israel and RALEIGH, N.C., June 3, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent notice of allowance for opaganib[4] in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response, providing protection for opaganib's potential use with a range of approved and in-development immune checkpoint inhibitors (ICIs) across a growing range of indications through 2040. The patent will be issued by the Chinese National Intellectual Property Administration (CNIPA) (Chinese Patent Application No.: 202080013805.3 issued May 24, 2024). "ICIs have become a cornerstone in cancer treatment, having been hailed as a major breakthrough by oncologists, with the global ICI market expected to exceed $100 billion by 2028, including Merck's Keytruda (pembrolizumab) and BMS' Yervoy (ipilimumab)," said Guy Goldberg, RedHill's Chief Business Officer. "This exciting new patent is based on compelling data from a range of in vivo experiments showing significant improvements in outcomes in combination with selected ICIs. China has been a world leader in embracing ICI-based therapy[5] and this is an important addition to the strong patent portfolio protecting opaganib." About Opaganib (ABC294640) Opaganib, a proprietary investigational host-directed and potentially broad-acting drug, is a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple potential diseases, including prostate cancer and cholangiocarcinoma (bile duct cancer), gastrointestinal acute radiation syndrome (GI-ARS), Sulfur Mustard exposure, COVID-19, Ebola and other viruses as part of pandemic preparedness. Opaganib's host-directed action is thought to work through the inhibition of multiple pathways, the induction of autophagy and apoptosis, and disruption of viral replication, through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (SPHK2, DES1 and GCS). Opaganib has been selected for evaluation by two U.S. government countermeasures programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure, both funded by the NIH: The Radiation and Nuclear Countermeasures Program (RNCP), led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the HHS National Institutes of Health, for the nuclear medical countermeasures (MCM) product development pipeline selected opaganib for development as a potential treatment for Acute Radiation Syndrome (ARS); and the Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by the Administration for Strategic Preparedness and Response (ASPR) / Biomedical Advanced Research and Development Authority (BARDA) and NIH/NIAID selected opaganib for evaluation as a potential medical countermeasure (MCM) against Sulfur Mustard exposure. Opaganib has demonstrated antiviral activity against SARS-CoV-2, multiple variants, and several other viruses, such as Influenza A and Ebola. Opaganib delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease. Opaganib also recently demonstrated a distinct synergistic effect when combined individually with remdesivir (Veklury®, Gilead Sciences Inc.), significantly improving potency while maintaining cell viability, in a U.S. Army-funded and conducted in vitro Ebola virus study. Being host-targeted, and based on data accumulated to date, opaganib is expected to maintain effect against emerging viral variants. In prespecified analyses of Phase 2/3 clinical data in hospitalized patients with moderate to severe COVID-19, oral opaganib demonstrated improved viral RNA clearance, faster time to recovery and significant mortality reduction in key patient subpopulations versus placebo on top of standard of care. Opaganib has demonstrated its safety and tolerability profile in more than 470 people in multiple clinical studies and expanded access use. Data from the opaganib global Phase 2/3 study was published in medRxiv. Opaganib has received Orphan Drug designation from the FDA for the treatment of cholangiocarcinoma and has undergone studies in advanced cholangiocarcinoma (Phase 2a) and prostate cancer. Opaganib also has a Phase 1 chemoradiotherapy study protocol ready for FDA-IND submission. Opaganib has also shown positive preclinical results in renal fibrosis, and has the potential to target multiple oncology, radioprotection, viral, inflammatory, and gastrointestinal indications. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[6], and Aemcolo®, for the treatment of travelers' diarrhea in adults[7]. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first -in -class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with U.S. government collaborations for development for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure, a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 ( upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease. More information about the Company is available at / twitter.com/RedHillBio. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements, including, but not limited to, statements regarding the intended use of net proceeds from the offering, may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding the risk that the Company will not comply with the listing requirements of the Nasdaq Capital Market ("Nasdaq") to remain listed for trading on Nasdaq, the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107, the risk that HB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required, as well as risks and uncertainties associated with the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia® and Aemcolo®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. Category: R&D Logo: [1] The allowed claims cover a pharmaceutical composition comprising opaganib and immune checkpoint inhibitors anti-PD-L1 antibody, an anti-PD-1 antibody, and/or an anti-CTLA4 antibody, the combination of opaganib and anti-PD1/anti-PDL1 for treatment of melanoma; combination of opaganib and anti-CTL4 for treatment of lung cancer. [2] Jin Y, Li H, Zhang P, Yu M, Zhang H, Li X. The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study. Int J Cancer. 2023 Jun 1;152(11):2351-2361. doi: 10.1002/ijc.34427. Epub 2023 Jan 18. PMID: 36632000. [3] GlobalData: Thematic Intelligence: Immuno-oncology (2023). Report Code: GDHCHT393, May 2023 [4] Opaganib is an investigational new drug, not available for commercial distribution. [5] Jin Y, Li H, Zhang P, Yu M, Zhang H, Li X. The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study. Int J Cancer. 2023 Jun 1;152(11):2351-2361. doi: 10.1002/ijc.34427. Epub 2023 Jan 18. PMID: 36632000. [6] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . [7] Aemcolo® (rifamycin) is indicated for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in adults. For full prescribing information see: . SOURCE RedHill Biopharma Ltd.

临床结果临床2期免疫疗法临床3期孤儿药

2024-05-18

·梅斯医学

阿奇霉素致死案例分析，12种混搭风要牢记！

阿奇霉素是临床常用的抗生素，是在红霉素结构上修饰后得到的一种广谱抗生素，同罗红霉素一样，属大环内酯类第二代抗生素。适用于敏感菌所致的呼吸道、皮肤软组织感染和衣原体所致的传播性疾病。临床上在应用阿奇霉素时，有很多危险的应用禁忌，不规范的用药可能引发严重后果，甚至会导致患者死亡！12岁儿童服用阿奇霉素死亡诊断：王某，男，12岁，中耳炎。治疗：医生开了5天剂量的阿奇霉素。服用4天后，患者出现心跳加速，晕眩以及作呕状态。被送到急诊室，在心脏监视器看到长QT，很快引发多形性心室性心律不整，抢救后不治死亡。分析：阿奇霉素有延长QT间期的副作用。绝大多数患者服用阿奇霉素是没有问题的，恰恰这位12岁的儿童患有先天性心脏疾病，本该选用另一种抗生素。阿奇霉素+复方甘草片/辛伐他汀=？诊断：患者，男，75岁，患慢性心力衰竭，长期服用地高辛（0.125mg/日）和辛伐他汀（40mg/日）。因出现发热、咳嗽、咽喉肿痛，前去医院就诊，被诊断为上呼吸道感染。治疗：阿奇霉素片，每次0.5g，每日一次；复方甘草片，每次4片，每日三次。出乎意料的是，患者用药3天后死亡。分析：是什么药物因素导致了患者死亡？在用药的时候，需要根据患者的具体情况对症用药，还需要注意药物之间的搭配禁忌。使用阿奇霉素需要注意以下几点：1.阿奇霉素和复方甘草片二者合用，易引起心律失常所有大环内酯类药物，均有QT间期延长、心室颤动、尖端扭转型室性心动过速等严重不良反应。当患者处于促心律失常状态（如未纠正的低钾血症、低镁血症）不能使用。复方甘草片的主要成分甘草甜素在体内水解成甘草次酸，具有盐皮质激素样作用。作用于肾远曲小管引起钾的流失，临床中可以见到引发低血钾的病例。提醒：当阿奇霉素与复方甘草片合用时应注意观察心电图QT间期的变化，适当补充钾剂，防止出现不良反应。2.阿奇霉素和辛伐他汀二者合用，易引起肝坏死辛伐他汀、阿托伐他汀由肝药酶CYP3A4代谢，是CYP3A4酶的底物，而阿奇霉素等大环内酯类为CYP3A4抑制剂，两者合用发生相互作用，使他汀类药物血浆浓度上升，可引起急性肝坏死。提醒：当阿奇霉素与辛伐他汀合用时，必须控制辛伐他汀的日剂量在20mg以内。阿奇霉素可能引起重症肌无力诊断：患者，女，68岁，既往患重症肌无力两年。治疗：因咳嗽、咳痰给予阿奇霉素0.5g静滴。当药物静点后约2小时，患者于活动中出现四肢无力加重、胸闷、呼吸困难、咳嗽、咳痰无力、吞咽困难。重症肌无力患者，立即给予吸氧及新斯的明1mg肌注后约20分钟，呼吸困难、胸闷及咳嗽无力症状缓解，恢复如前。第二日常规再次给予阿奇霉素0.5g静点后，患者于静点中再次出现同样症状，肌注新斯的明后缓解。第三日停用阿霉素后，一直无呼吸困难及咳嗽无力等症状发生。分析：大环内酯类抗生素（阿奇霉素、克拉霉素），与氨基糖苷类和喹诺酮类抗生素一样，可以导致肌无力症状的加剧，以至诱发危象的发生。故这些药物在重症肌无力患者的治疗中应慎用或者禁用。阿奇霉素的不良反应1.阿奇霉素+麦角类衍生物：麦角类衍生物与阿奇霉素合用后可增加急性麦角中毒，出现恶心、呕吐和血管痉挛性贫血等风险，因此禁止阿奇霉素与麦角类衍生物联用。2.阿奇霉素+匹莫齐特：匹莫齐特与阿奇霉素合用可增加发生心脏毒性的几率，出现QT延长、尖端扭转型室性心动过速、心脏停搏等风险，因此禁止阿奇霉素与匹莫齐特联用。3.阿奇霉素+环孢素：环孢素与阿奇霉素合用后，环孢素可增加阿奇霉素的血药浓度，因此两药物应避免联用，如需联用时应密切监测环孢素的血药浓度并适时调整其使用剂量。4.阿奇霉素+华法林：长期服用华法林的患者应用阿奇霉素后可导致凝血酶原时间延长，从而增加出血的风险性，因此服用华法林的患者应避免使用阿奇霉素。5.阿奇霉素+地高辛：阿奇霉素可改变胃肠菌群，提高地高辛的生物利用度，从而抑制地高辛的肾排泄，因此两药物联用期间建议加强地高辛血清浓度监测，在使用阿奇霉素期间或者停用阿奇霉素后至少1个月内，需降低地高辛的使用剂量。6.阿奇霉素+利福平：利福平诱导肝微粒体酶，可增强阿奇霉素的代谢清除，阿奇霉素抑制肝微粒体酶，可减弱利福平的代谢清除，因此两药物联用后由于可以减少利福平的使用剂量，因此建议适当增加阿奇霉素的使用剂量。7.阿奇霉素+地衣芽孢杆菌活菌制剂：阿奇霉素与地衣芽孢杆菌活菌制剂合用时可降低其疗效，因此地衣芽孢杆菌活菌制剂不宜与阿奇霉素联用，必要时可间隔3小时服用。8.阿奇霉素+多潘立酮：多潘立酮主要经CYP3A4代谢，而阿奇霉素可显著抑制肝药酶的活性，因此多潘立酮与阿奇霉素联用后会导致多潘立酮的血药浓度升高以及QT间期轻度延长，故两药物不宜联用。9.阿奇霉素+茶碱类药物：阿奇霉素与茶碱类药物联用后会抑制茶碱类药物的代谢，促使茶碱类药物血药浓度升高，增强疗效，因此联用时茶碱类药物应适当减量使用。10.阿奇霉素+药用炭：药用炭具有吸附作用，与阿奇霉素联用后会因其吸附作用影响阿奇霉素治疗效果，因此两药物不宜联用。阿奇霉素注射制剂1.阿奇霉素注射制剂+热毒宁注射制剂：热毒宁注射制剂与阿奇霉素注射制剂配伍使用时溶液可出现浑浊或沉淀，因此热毒宁注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。2.阿奇霉素注射制剂+更昔洛韦注射制剂：阿奇霉素注射制剂与更昔洛韦注射制剂配伍使用时溶液可出现细小的絮状物，振摇后出现白色浑浊，能见度差，分析两药物间存在相互作用，因此更昔洛韦注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。3.阿奇霉素注射制剂+氨茶碱注射制剂：阿奇霉素注射制剂与氨茶碱注射制剂配伍使用时溶液出现絮状沉淀，因此氨茶碱注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。4.阿奇霉素注射制剂+炎琥宁注射制剂：阿奇霉素注射制剂与炎琥宁注射制剂配伍使用时溶液出现白色絮状物，放置2小时后白色絮状物仍无改变，因此炎琥宁注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。5.阿奇霉素注射制剂+呋塞米注射制剂：阿奇霉素注射制剂与呋塞米注射制剂配伍使用时溶液会出现白色絮状物，振荡后不消失，因此呋塞米注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。6.阿奇霉素注射制剂+奥美拉唑注射制剂：阿奇霉素注射制剂与奥美拉唑注射制剂配伍使用时溶液会出现变色反应，混合稀释5分钟后溶液变淡黄色，继续放置10分钟后溶液变深黄色，因此奥美拉唑注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。7.阿奇霉素注射制剂+泮托拉唑钠注射制剂：阿奇霉素注射制剂与泮托拉唑钠注射制剂配伍使用时溶液立即发生浑浊沉淀，轻轻震荡后沉淀消失，但10分钟后溶液逐渐变成橙黄色，因此泮托拉唑钠注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。8.阿奇霉素注射制剂+痰热清注射制剂：阿奇霉素注射制剂与痰热清注射制剂配伍使用时溶液出现絮状或片状沉淀物，放置30分钟后沉淀不消失并逐渐变成深褐色，因此痰热清注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。9.阿奇霉素注射制剂+头孢匹胺钠注射制剂：阿奇霉素注射制剂与头孢匹胺钠注射制剂配伍使用时溶液立即出现白色浑浊并产生沉淀物，放置24小时白色浑浊与沉淀物未见消失，因此头孢匹胺钠注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。10.阿奇霉素注射制剂+利福平注射制剂：阿奇霉素注射制剂与利福平注射制剂配伍使用时溶液立即出现豆腐渣样的沉淀物，混合溶液放置2小时后，仍出现豆腐渣样沉淀物，因此利福平注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。11.阿奇霉素注射制剂+氨溴索注射制剂：阿奇霉素注射制剂与氨溴索注射制剂配伍使用时溶液立即出现乳白色混浊絮状物，将其放置24小时后混浊絮状物未溶解反而增加，因此氨溴索注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。12.阿奇霉素注射制剂+利福霉素注射制剂：阿奇霉素注射制剂与利福霉素注射制剂配伍使用时溶液会出现橘黄色混浊，放置10分钟后出现橘黄色絮状物，继续放置2小时后絮状物未见消失，因此利福霉素注射制剂不宜与阿奇霉素注射制剂在同一容器内混合使用。阿奇霉素剂型多样，既有口服制剂也有注射制剂，虽然具有一定耐药率，但是应用仍然没有减少，尤其干混悬剂型在临床中应用颇为广泛。在使用阿奇霉素时应注意单独静脉滴注，在与另一种药物进行静脉滴注时不宜序贯输注，应在两药物之间使用生理盐水或者其他液体间隔输注，避免发生配伍禁忌对患者造成不良反应以及产生药物浪费的情况，在使用药物过程中也应密切监测输液过程及时发现不良症状及时进行对症治疗，以免引起严重后果。用药建议1.临床上医师、护士在应用药物时，要仔细阅读说明书，掌握用法、用量、注意事项、配伍禁忌等；2.加强输液中的观察和巡视，对于特殊用药、新药更要观察仔细，防止意外发生；3.输液过程中，发现药物有变色、浑浊、沉淀等现象，应立即停止输液，更换输液器和液体，根据病情选择葡萄糖注射液或氯化钠注射液在两种可疑药物之间间隔，最好不将有配伍禁忌的药物联合使用。4.尤其儿科临床中，做好解释工作，用药慎之又慎，减少不必要的医疗纠纷。来源｜医者部落/今日头条、医学界呼吸频道编辑 | rayms授权转载及爆料请联络梅斯医学管理员点击下方“阅读原文” 下载梅斯医学APP吧！

2024-05-06

·BioSpace

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intellectual property portfolio across multiple indications -- U.S. Army studies suggest that opaganib may be the first host-directed molecule to show activity in vivo in Ebola virus disease, delivering a statistically significant increase in survival; separately, opaganib demonstrated robust synergistic effect in vitro when combined with remdesivir (Veklury®; Gilead Sciences, Inc.), improving viral inhibition while maintaining cell viability -- A host-directed and potentially broad acting twice-daily oral, small molecule, opaganib is in development for multiple indications, including COVID-19, acute respiratory distress syndrome, oncology and two U.S. government-sponsored countermeasures programs for Acute Radiation Syndrome and Sulfur Mustard exposure. It has a demonstrated safety and efficacy profile, and is well-suited to counter nuclear / chemical exposure and viral pandemic scenarios, being viral mutation-resistant, and easy to administer and distribute TEL-AVIV, Israel and RALEIGH, N.C., May 6, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024). "This new patent adds to the existing intellectual property portfolio protecting opaganib across multiple indications and represents the first China patent in the Ebola patent family," said Guy Goldberg, RedHill's Chief Business Officer. "U.S. Army studies suggest that opaganib may be the first host-directed molecule to show activity in vivo in Ebola virus disease, delivering a statistically significant increase in survival. Targeting multiple indications, including selection by two U.S. government countermeasures programs for Acute Radiation Syndrome and Sulfur Mustard exposure, oral opaganib, has a demonstrated safety and efficacy pro is well-suited to viral pandemic scenarios, being viral mutation-resistant, and easy to administer and distribute." About Ebola virus disease: According to the Centers for Disease Control and Prevention (CDC), Ebola disease is a rare and often deadly illness, caused by infection by one of a group of four viruses, known as ebolaviruses, that are found primarily in sub-Saharan Africa and are known as: Zaire, Sudan, Taï Forest (formerly Côte d'Ivoire) and Bundibugyo. Transmission of the disease is mostly through contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with an ebolavirus. The course of the illness typically progresses from "dry" symptoms initially (such as fever, aches and pains, and fatigue), and then progresses to "wet" symptoms (such as diarrhea, vomiting and unexplained hemorrhaging, bleeding or bruising) as the person becomes sicker. There are currently only two FDA-approved therapies to treat EVD caused by the Ebola virus, species Zaire ebolavirus, in adults and children; Inmazeb™ (atoltivimab/maftivimab/odesivimab, Regeneron Pharmaceuticals, Inc), a combination of three monoclonal antibodies and Ebanga™ (ansuvimab-zykl, Ridgeback Biotherapeutics, LP), a single monoclonal antibody. Both are intravenously infused direct acting monoclonal antibody antivirals that bind to glycoproteins on the Ebola virus's surface to prevent the virus from entering a person's cells. There is an urgent need for host-directed small molecule therapies that may be effective against multiple strains of ebolavirus, less likely to be impacted by viral mutation, and that are easy to store, distribute and administer, especially in areas where healthcare services and infrastructures may be sub-optimal. About Opaganib (ABC294640) Opaganib, a proprietary investigational host-directed and potentially broad-acting drug, is a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple potential diseases, including gastrointestinal acute radiation syndrome (GI-ARS), COVID-19, other viruses as part of pandemic preparedness, and cholangiocarcinoma (bile duct cancer). Opaganib's host-directed action is thought to work through the inhibition of multiple pathways, the induction of autophagy and apoptosis, and disruption of viral replication, through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (SPHK2, DES1 and GCS). Opaganib was selected by the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP), led by the National Institute of Allergy and Infectious Diseases, part of the HHS National Institutes of Health, for the nuclear medical countermeasures product development pipeline as a potential treatment for Acute Radiation Syndrome (ARS). Opaganib has demonstrated antiviral activity against SARS-CoV-2, multiple variants, and several other viruses, such as Influenza A and Ebola. Opaganib delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease. Opaganib also recently demonstrated a distinct synergistic effect when combined individually with remdesivir (Veklury®, Gilead Sciences Inc.), significantly improving potency while maintaining cell viability, in a U.S. Army-funded and conducted in vitro Ebola virus study. Being host-targeted, and based on data accumulated to date, opaganib is expected to maintain effect against emerging viral variants. In prespecified analyses of Phase 2/3 clinical data in hospitalized patients with moderate to severe COVID-19, oral opaganib demonstrated improved viral RNA clearance, faster time to recovery and significant mortality reduction in key patient subpopulations versus placebo on top of standard of care. Opaganib has demonstrated its safety and tolerability pro more than 470 people in multiple clinical studies and expanded access use. Data from the opaganib global Phase 2/3 study was published in medRxiv. Opaganib has received Orphan Drug designation from the FDA for the treatment of cholangiocarcinoma and has undergone studies in advanced cholangiocarcinoma (Phase 2a) and prostate cancer. Opaganib also has a Phase 1 chemoradiotherapy study protocol ready for FDA-IND submission. Opaganib has also shown positive preclinical results in renal fibrosis, and has the potential to target multiple oncology, radioprotection, viral, inflammatory, and gastrointestinal indications. About RedHill Biopharma RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[2], and Aemcolo®, for the treatment of travelers' diarrhea in adults[3]. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease. More information about the Company is available at / twitter.com/RedHillBio. [1] Opaganib is an investigational new drug, not available for commercial distribution. [2] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . [3] Aemcolo® (rifamycin) is indicated for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in adults. For full prescribing information see: . Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements, including, but not limited to, statements regarding the intended use of net proceeds from the offering, may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding the risk that the Company will not comply with the listing requirements of the Nasdaq Capital Market ("Nasdaq") to remain listed for trading on Nasdaq, the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107, the risk that HB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required, as well as risks and uncertainties associated with the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia® and Aemcolo®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. Category: R&D Logo: View original content: SOURCE RedHill Biopharma Ltd. Company Codes: NASDAQ-SMALL:RDHL, Berlin:2RH0.BE, Frankfurt:2RH0.F, Munich:2RH0.MU, Stuttgart:2RH0.SG

临床结果临床2期孤儿药临床3期临床1期

100 项与利福霉素钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08480	利福霉素钠	D06AX15 J04AB03 S02AA12	DB11753

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
旅行者腹泻	美国	Redhill Biopharma, Inc.	2018-11-16
痢疾	芬兰	Dr. Falk Pharma GmbH	2018-11-04
肺结核	英国	Sandoz GmbH	2000-02-01
革兰氏阳性细菌感染	中国	成都第一制药有限公司	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腹泻型肠易激综合征	临床2期	比利时	Cosmo Technologies Ltd.	2017-12-18
腹泻型肠易激综合征	临床2期	德国	Cosmo Technologies Ltd.	2017-12-18
腹泻型肠易激综合征	临床2期	意大利	Cosmo Technologies Ltd.	2017-12-18
腹泻型肠易激综合征	临床2期	西班牙	Cosmo Technologies Ltd.	2017-12-18
憩室炎	临床2期	德国	Dr. Falk Pharma GmbH	2013-07-21
盲袢综合征	临床2期	美国	Cosmo Pharmaceuticals NV	-
梭菌感染	临床2期	墨西哥	Cosmo Pharmaceuticals NV	-
梭菌感染	临床2期	南非	Cosmo Pharmaceuticals NV	-
梭菌感染	临床2期	土耳其	Cosmo Pharmaceuticals NV	-
溃疡性结肠炎	临床2期	-	Cosmo Pharmaceuticals NV	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02969252 (Pubmed \| Antibiotics (Basel)) 人工标引	临床1期	-	18	Rifamycin SV	網構鬱簾襯鬱憲鏇壓鏇(顧醖鑰鬱選鏇壓製築膚) = including diarrhea-predominant irritable bowel syndrome, hepatic encephalopathy 遞網遞壓窪憲選醖齋製 (遞鹽構蓋鏇糧廠艱艱繭 )	积极	2021-02-06
NCT01208922 (CTgov)	临床3期	痢疾 \| 旅行者腹泻 \| 急性腹泻	835	Rifamycin SV-MMX® (Group A)	鹽醖鬱鹽醖範願餘衊糧(網觸範網觸鏇簾餘鬱網) = 鑰窪繭衊遞觸製壓觸鏇醖鹹廠壓繭齋夢鏇獵餘 (廠襯築齋遞夢遞鏇築憲, 範觸鑰獵廠襯繭淵願膚 ~ 夢蓋選選繭廠鏇艱壓範) 更多	-	2019-02-27
				ciprofloxacin (Group B)	鹽醖鬱鹽醖範願餘衊糧(網觸範網觸鏇簾餘鬱網) = 鏇鬱簾醖窪糧鏇糧壓網醖鹹廠壓繭齋夢鏇獵餘 (廠襯築齋遞夢遞鏇築憲, 廠繭蓋獵壓製鏇積衊夢 ~ 齋夢膚鑰築鹹構壓襯鹹) 更多
NCT03447821 (CTgov)	临床2期	痢疾	40	400 mg Rifamycin SV dosage (400 mg Rifamycin SV Dosage)	鏇齋顧獵製獵廠鑰衊鏇(簾餘遞蓋積衊鬱壓願窪) = 遞觸壓齋鏇繭夢構夢襯選鹽糧壓積艱鑰觸憲膚 (鹹構簾遞鏇築衊憲顧選, 積鹽齋範遞餘憲構窪網 ~ 糧淵簾鑰鹹選廠繭網醖) 更多	-	2018-10-09
				800 mg Rifamycin SV dosage (800 mg Rifamycin SV Dosage)	鏇齋顧獵製獵廠鑰衊鏇(簾餘遞蓋積衊鬱壓願窪) = 製齋網淵範遞衊鹽窪築選鹽糧壓積艱鑰觸憲膚 (鹹構簾遞鏇築衊憲顧選, 鹹鹹窪遞網憲範觸廠衊 ~ 齋糧遞構餘衊艱積鬱選) 更多
NCT01142089 (CTgov)	临床3期	旅行者腹泻	264	Placebo (Placebo)	齋窪網鏇鹽襯構廠鹽築(襯鏇廠構齋糧壓鏇壓繭) = 簾獵選鹹選築構醖願遞顧獵鬱醖鏇網鑰夢鏇鹽 (網願鹽醖選襯廠構餘窪, 構淵襯衊糧範範觸廠鬱 ~ 蓋衊觸遞襯願遞繭繭遞) 更多	-	2018-04-10
				Rifamycin SV MMX (Rifamycin SV MMX)	齋窪網鏇鹽襯構廠鹽築(襯鏇廠構齋糧壓鏇壓繭) = 範積憲繭襯鏇夢艱簾範顧獵鬱醖鏇網鑰夢鏇鹽 (網願鹽醖選襯廠構餘窪, 鏇壓網醖憲觸遞憲醖積 ~ 觸膚鏇膚衊範鹹遞襯製) 更多